Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial.
NeoStem, which later changed its name to Caladrius BioScience, ran a Phase 3 trial targeting cancer stem cells. These cells are believed to be able to survive chemotherapy and other…
